- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01212523
Effects of Propofol and Isoflurane on Pulmonary Vascular Resistance
December 14, 2011 updated by: Michelle White, University Hospitals Bristol and Weston NHS Foundation Trust
Randomised Cross-over Pilot Study to Determine the Effects of Isoflurane and Propofol on Pulmonary Vascular Resistance in Children With Pulmonary Hypertension.
The investigators hypothesize that there is no difference between the effects of isoflurane and propofol anaesthesia on pulmonary vascular resistance (PVR).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
10
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Bristol, United Kingdom, BS2 8BJ
- UH bristol NHS Trust
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
3 months to 16 years (CHILD)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- All children between 3 months and 16 years of age with pulmonary arterial hypertension undergoing a PVR study.
Exclusion Criteria:
- Children with a known adverse reaction to one of the study drugs eg malignant hyperpyrexia or a disorder of fatty acid oxidation.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: DIAGNOSTIC
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The primary endpoint is the percentage change in PVR under isoflurane anaesthesia compared with propofol anaesthesia.
Time Frame: 2 hours
|
2 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The secondary endpoints are the percentage change in mean pulomanry artery pressure (PAP), systemic vascular resistance (SVR) and mean arterial pressure (MAP).
Time Frame: 2 hours
|
2 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (ACTUAL)
December 1, 2011
Study Completion (ACTUAL)
December 1, 2011
Study Registration Dates
First Submitted
November 4, 2009
First Submitted That Met QC Criteria
September 29, 2010
First Posted (ESTIMATE)
September 30, 2010
Study Record Updates
Last Update Posted (ESTIMATE)
December 15, 2011
Last Update Submitted That Met QC Criteria
December 14, 2011
Last Verified
December 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Hypertension
- Hypertension, Pulmonary
- Physiological Effects of Drugs
- Central Nervous System Depressants
- Anesthetics, Intravenous
- Anesthetics, General
- Anesthetics
- Hypnotics and Sedatives
- Anesthetics, Inhalation
- Propofol
- Isoflurane
Other Study ID Numbers
- CH/2007/2476
- 2009-010614-30 (REGISTRY: EudraCT)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension, Pulmonary
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
VIVUS LLCNot yet recruitingPulmonary Arterial Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension (PAH) | Pulmonary Arterial Hypertension WHO Group I | Pulmonary Arterial Hypertension PAH
-
Rutgers, The State University of New JerseyRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) | Pulmonary Arterial Hypertension of Congenital Heart Disease | Pulmonary Arterial Hypertension Associated With Schistosomiasis (Disorder) | Pulmonary Arterial and Chronic Thromboembolic... and other conditionsUnited States
-
Poitiers University HospitalNot yet recruitingChronic Thromboembolic Pulmonary Hypertension (CTEPH) | Pulmonary Arterial Hypertension (PAH)
-
Centre Chirurgical Marie LannelongueUnknownChronic Thrombo-embolic Pulmonary Hypertension and Pulmonary Arterial HypertensionFrance
-
Guangdong Provincial People's HospitalRecruitingIdiopathic Pulmonary HypertensionChina
-
Philipps University MarburgMSD Sharp & Dohme GmbH, GermanyNot yet recruiting
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
University of Kansas Medical CenterRecruitingPulmonary Arterial Hypertension | Pulmonary Hypertension | Chronic Thromboembolic Pulmonary Hypertension | Pulmonary Hypertension Due to Left Heart Disease | Pulmonary Hypertension, Primary, 4 | Pulmonary Hypertension, Primary, 2 | Pulmonary Hypertension, Primary, 3 | Pulmonary Hypertension, Primary and other conditionsUnited States
-
Stanford UniversityNational Heart, Lung, and Blood Institute (NHLBI); University of MichiganNot yet recruitingPulmonary Arterial Hypertension (PAH)United States
Clinical Trials on propofol and isoflurane
-
Superior UniversityActive, not recruiting
-
UPECLIN HC FM Botucatu UnespFundação de Amparo à Pesquisa do Estado de São PauloCompletedPatients in Good HealthBrazil
-
Rutgers, The State University of New JerseyTerminated
-
Aga Khan UniversityCompleted
-
Duke UniversityUS Department of Veterans AffairsCompletedKnee Osteoarthritis | Hip Osteoarthritis | Cervical Spondylosis | Lumbar SpondylosisUnited States
-
Mansoura UniversityCompletedTotal Laryngectomy | Cancer LarynxEgypt
-
Duke UniversityCompletedPostoperative Delirium | Alzheimers Disease | Post Operative Cognitive DysfunctionUnited States
-
Instituto de Investigación Hospital Universitario...Instituto de Salud Carlos IIIRecruiting
-
Institute of Liver and Biliary Sciences, IndiaInstitute of Liver and Biliary SciencesRecruitingLiver Transplant RecipientsIndia
-
Sedana MedicalCritical Illness, Brain Dysfunction, and Survivorship CenterActive, not recruitingSedation | Post-Intensive Care SyndromeUnited States